SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing extreme volatility driven by a major follow-on order for its 800G optical transceivers and intensifying speculation surrounding its role in hyperscale data center infrastructure. While the community is actively debating the company's valuation and reliance on a single key customer, bulls point to a massive production pipeline and long-term capacity expansion as structural catalysts for growth.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending as investors digest the company's disclosure of a multi-year order backlog extending through 2028, reinforcing its role as a critical supplier for AI data center infrastructure. The stock has seen massive price appreciation fueled by significant strategic investments from industry leaders and high-conviction sentiment regarding its pivotal position in optical networking.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as traders debate whether it is currently in a resilient bull phase driven by AI capex demand or if it is a crowded, overextended bubble prone to a sharp mean reversion. While some market participants are aggressively positioning for a pullback, others are closely watching the sector's relative strength compared to lagging software stocks as a bellwether for broader market sentiment.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is seeing heightened attention following strong earnings results that highlighted robust performance in equities trading and investment banking. Market participants are actively discussing the bank's ability to navigate current market volatility, while debates continue regarding the broader financial sector's valuation and the impact of geopolitical and macroeconomic pressures on bank capital quality.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma Inc. is trending following contract awards from the U.S. government for quantum materials and high-speed datacom, signaling a potential shift toward commercialization that has sparked intense debate among investors. The community is sharply divided, with bulls pointing to the company's proprietary III-V-on-silicon platform and low-float potential, while vocal criticsciting lack of foundry partnerships and limited revenueare actively challenging the company's valuation and long-term viability.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXT Inc. is seeing intense community volatility driven by its status as a critical yet polarizing supplier of indium phosphide for AI data center optics. While some investors emphasize its dominant market position and essential role in high-speed connectivity, others are raising alarms over weak financials, heavy insider selling, and potential share dilution, leading to fierce debate between those betting on continued momentum and those calling for a bubble-like correction.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing heavy retail and institutional interest as investors bet on the companys electro-optic polymer technology as a scalable solution for AI data centers. The community is actively debating the transition from R&D to foundry-integrated manufacturing, with recent partnerships and expectations of upcoming tape-out results driving volatility and ongoing speculation about potential major industry acquisitions.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate as the token surges on rumors of high-profile integrations and its expansion into Web3 entertainment. While some traders are celebrating massive gains and pointing to upcoming global event partnerships as long-term catalysts, others remain deeply skeptical, frequently labeling the project a speculative pump-and-dump scheme.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is gaining significant momentum as investors digest recent FDA Orphan Drug Designations and progress in late-stage Phase 3 clinical trials for its pancreatic cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with analysts increasingly highlighting the company's robust pipeline and strategic importance in targeted oncology.

Maulcoin

Maulcoin is trending as a community-driven, Star Wars-themed meme coin, with supporters actively lobbying for a price chart on major platforms while sharing their experiences with holding through volatility. The community remains focused on collective buying efforts and long-term holding to drive up market capitalization, frequently highlighting the project's growth and their commitment to building a lasting cultural presence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tudor Investment Corp ET AL Raises Stock Position in NovoCure Limited $NVCR

Tudor Investment Corp ET AL boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to its most recent filing with the SEC. The institutional...

JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR

JPMorgan Chase & Co. lifted its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 104.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...

SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR

SG Americas Securities LLC boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 905.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,806 shares of the medical equipment provider...

Novocure to Report First Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast...

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages

Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat reports. One...

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -4.00% and -70.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.</li><li>In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.</li><li>Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, the objective response rate was 34.6%, while the median overall survival was 9.7 months.</li></ul>Novocure (NVCR) shares gained nearly 3% in Thursday’s opening trade after the company announced positive topline results in its metastatic pancreatic cancer therapy trial.Novocure stated that&nbsp;PANOVA-4 met its pre-specified primary endpoint&nbsp;in the Phase 2 trial, achieving a statistically significant improvement in disease control rate. The PANOVA-4 study is a pilot, single-arm study of Tumor Treating Fields (TTFields) concomitant with atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVCR">Novocure</a> trended in the ‘bullish’ territory. NVCR was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Novocure Therapy Improves Disease Control Rate</h2>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.“The positive results from the PANOVA-4 trial further support the potential of Tumor Treating Fields to improve outcomes in pancreatic cancer,” said Uri Weinberg, Chief Medical and Innovation Officer, Novocure.Secondary endpoints in PANOVA-4 included objective response rate (ORR) and overall survival (OS). Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, ORR was 34.6%, while median OS was 9.7 months.Additional secondary endpoints included progression-free survival, one-year survival rate, six-month progression-free survival, duration of response, and incidence of treatment-emergent adverse events.The company stated that TTFields therapy was well-tolerated, and device-related safety was consistent with prior clinical studies.<h2 class="st-heading-2">What Does Novocure Do?</h2>Novocure is a Switzerland-based company that is currently developing and commercializing its Tumor Treating Fields therapy. Its commercialized products have been approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma.<a href="https://stocktwits.com/symbol/NVCR">NVCR stock</a> is down 10% year-to-date and 38% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 22% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, NovoCure Limited logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial

Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.

Equity

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma...

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -28.18% and -66.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR

Tudor Investment Corp ET AL lifted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 606,070 shares of the medical equipment provider's stock after purch...

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NVCR
NovoCure Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVCR News

NVCRNovoCure Ltd